Kingo Kanda

Real‐world outcomes of pembrolizumab monotherapy in <scp>non‐small</scp> cell lung cancer in Japan: A post‐marketing surveillance

Nobuyuki Yamamoto, Tetsu Kamitani, Kingo Kanda et al. · Cancer Science · 2022 · 13 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

Yasushi Goto, Atsuhisa Tamura, Hirotaka Matsumoto et al. · JTO Clinical and Research Reports · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacology +16

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan

Hiroshi Nokihara, Takashi Kijima, Toshihide Yokoyama et al. · Cancers · 2022 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +17